Dr. Pergola is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
16620 San Pedro Ave
Ste 300
San Antonio, TX 78232
Summary
- Dr. Pablo Pergola is a nephrologist based in San Antonio, TX, specializing in general nephrology, acute renal failure, chronic kidney disease, urinary tract infections, and diabetic nephropathy. He completed his residency in Internal Medicine and fellowship in Nephrology at the University of Texas Health Science Center San Antonio. His publications cover topics such as kidney disease treatments and therapies, with research featured in several high-impact journals. Dr. Pergola has participated in notable clinical trials, including studies on diabetic kidney disease and Alport syndrome. He was recognized with the CMS Meaningful Use Stage 1 Certification for his work with eClinicalWorks EHR.
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Nephrology, 1997 - 1999- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 1994 - 1997
Univ Salvador- Fac MedClass of 1988
Certifications & Licensure
TX State Medical License 1998 - 2026- American Board of Internal Medicine Nephrology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Nephrology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Clinical Trials
- Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia Start of enrollment: 2010 Sep 01
- Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis Start of enrollment: 2014 Mar 01
- A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL Start of enrollment: 2017 Mar 02
- Join now to see all
Publications & Presentations
PubMed
- Safety and Phosphate-Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers.Pablo E Pergola, Melanie S Joy, Armando Garsd, Steve J Hasal, Atul Khare
Clinical and Translational Science. 2025-01-01 - 1 citationsSelonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.Hiddo J L Heerspink, Vlado Perkovic, Katherine R Tuttle, Pablo E Pergola, Kenneth W Mahaffey
Journal of the American Society of Nephrology. 2024-12-01 - Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease.Pamela Navarro-Gonzales, Tomas Ganz, Pablo E Pergola, Anna Zuk, Kevin Dykstra
Clinical Pharmacology and Therapeutics. 2024-10-01
Press Mentions
KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase IOctober 28th, 2024
Reata Pharma Shares Trading Higher After Reacquiring U.S. And Worldwide Licensing RightsOctober 14th, 2019
Reata Announces Presentations at the 56thCongress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA)June 4th, 2019- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
